Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vancomycin-resistant enterococci.

A J McGeer1, D E Low

  • 1Department of Microbiology, Mount Sinai Hospital, Toronto, Ontario, Canada. amcgeer@mtsinai.on.ca

Seminars in Respiratory Infections
|February 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contemporary outcomes of left thoraco-abdominal esophagectomy due to cancer in the esophagus or gastroesophageal junction, a multicenter cohort study.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2024
Same author

Correction: ERAS guidelines-driven upper gastrointestinal contrast study after esophagectomy can detect delayed gastric conduit emptying and improve outcomes.

Surgical endoscopy·2023
Same author

ERAS guidelines-driven upper gastrointestinal contrast study after esophagectomy can detect delayed gastric conduit emptying and improve outcomes.

Surgical endoscopy·2022
Same author

Canadian Surgery Forum.

Canadian journal of surgery. Journal canadien de chirurgie·2022
Same author

Fit-for-Discharge Criteria after Esophagectomy: An International Expert Delphi Consensus.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2020
Same author

Carbapenemase-producing Enterobacterales in hospital drains in Southern Ontario, Canada.

The Journal of hospital infection·2020
Same journal

TB vaccines at the turn of the century: insights into immunity to M. tuberculosis and modern approaches for prevention of an ancient disease.

Seminars in respiratory infections·2003
Same journal

Environmental infection control of tuberculosis.

Seminars in respiratory infections·2003
Same journal

Mycobacterium tuberculosis: the treatment of active disease.

Seminars in respiratory infections·2003
Same journal

Pediatric tuberculosis.

Seminars in respiratory infections·2003
Same journal

Clinical and radiographic features of HIV-related tuberculosis.

Seminars in respiratory infections·2003
Same journal

Treatment of latent tuberculosis infection.

Seminars in respiratory infections·2003
See all related articles

Vancomycin-resistant enterococci (VRE) are a growing hospital threat, especially in ICUs. Prevention programs are crucial for patient safety and likely cost-effective despite initial expenses.

Area of Science:

  • Infectious Diseases
  • Hospital Epidemiology
  • Antimicrobial Resistance

Background:

  • Enterococci have transitioned from low-impact organisms to significant hospital-acquired pathogens.
  • Vancomycin-resistant enterococci (VRE) demonstrate a steady increase in prevalence, particularly in intensive care units (ICUs).
  • VRE infections pose therapeutic challenges, especially when bactericidal antimicrobial activity is required.

Purpose of the Study:

  • To highlight the increasing clinical impact and challenges associated with Vancomycin-resistant enterococci (VRE).
  • To discuss emerging treatment options for VRE infections.
  • To emphasize the need for cost-effectiveness data on VRE prevention programs.

Main Methods:

  • Review of epidemiological trends in enterococcal infections and vancomycin resistance.

Related Experiment Videos

  • Discussion of current and novel antimicrobial therapies for VRE.
  • Analysis of the economic implications of VRE endemicity and prevention.

    • Main Results:

    • VRE constituted 26% of nosocomial enterococci in 1999, with a significant rise from 1994-1998.
    • Over 25% of enterococci in ICUs exhibit vancomycin resistance.
    • New agents like quinipristin-dalfopristin and linezolid offer treatment options for VRE infections.

    Conclusions:

    • VRE has become endemic in many healthcare settings, posing substantial risks and costs.
    • Effective VRE transmission control is complex and resource-intensive but essential.
    • While data are limited, VRE prevention programs are likely cost-saving due to the high cost of VRE infections.